News | August 03, 2021
Morepen Laboratories posts Q1FY22 consolidated PAT of Rs. 30.47 Cr
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
The highest reduction in prices for Pulse Oximeters, Blood Pressure Monitoring Machine and Nebulizer has been reported by importers
Complementary business models are the reason for the acquisition
The govt has rolled out three schemes for promoting the manufacture of API
It works as an adjunct to standard care based on robust clinical trials
India business is growing as per projections; whereas US business will bounce back soon.
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Price band in the range of Rs 933 to Rs 954
Subscribe To Our Newsletter & Stay Updated
